Kimberly-Clark is shopping for Tylenol maker Kenvue in a money and inventory deal value about $48.7 billion, creating a large client well being items firm.

Shareholders of Kimberly-Clark will personal about 54% of the mixed firm. Kenvue shareholders will personal about 46% in what is among the largest company takeovers this yr.

The mixed firm may have an enormous secure of family manufacturers underneath one roof, placing Kenvue’s Listerine mouthwash and Band-Support side-by-side with Kimberly-Clark’s Cottonelle rest room paper, Huggies and Kleenex tissues. It should additionally generate about $32 billion in annual income.

Kenvue has spent a comparatively temporary interval as an impartial firm, having been spun off by Johnson & Johnson two years in the past. J&J first introduced in late 2021 that it was splitting its slow-growth client well being division from the pharmaceutical and medical gadget divisions.

Kenvue has since been focused by activist buyers sad concerning the trajectory of the corporate and Wall Road appeared to anticipate some heavy lifting forward for Kimberly-Clark.

Shares of Kimberly-Clark, based mostly in simply outdoors of Dallas, slumped 13% Monday. Kenvue’s inventory jumped greater than 15%.

Kenvue and Tylenol have been thrust into the nationwide highlight this yr as President Donald Trump and Well being Secretary Robert F. Kennedy Jr. promoted unproven and in some instances discredited ties between Tylenol, vaccines and the complicated mind dysfunction autism.

Trump then urged pregnant girls towards utilizing the medication. That went past Meals and Drug Administration recommendation that medical doctors “ought to think about minimizing” the painkiller acetaminophen’s use in being pregnant — amid inconclusive proof about whether or not an excessive amount of could possibly be linked to autism.

Kennedy reiterated the FDA steerage throughout a press convention final week. He mentioned that there isn’t enough proof to hyperlink the drug to autism.

“We now have requested physicians to reduce the use to when its completely crucial,” he mentioned.

Kenvue has continued to push again on the Trump administration’s dialogue.

“Nothing is extra necessary to us than the well being and security of the individuals who use our merchandise,” Kenvue mentioned in a press release on its web site. “We imagine impartial, sound science clearly reveals that taking acetaminophen doesn’t trigger autism. We strongly disagree with allegations that it does and are deeply involved concerning the well being dangers and confusion this poses for anticipating moms and fogeys.”

In July Kenvue, introduced that CEO Thibaut Mongon was leaving within the midst of a strategic evaluate with the corporate underneath mounting stress from activist buyers.

Kimberly-Clark Chairman and CEO Mike Hsu will likely be chairman and CEO of the mixed firm. Three members of the Kenvue’s board will be part of Kimberly-Clark’s board at closing. The mixed firm will preserve Kimberly-Clark’s headquarters in Irving, Texas, however there will likely be vital operations round Kenvue amenities and places as effectively.

The deal is predicted to shut within the second half of subsequent yr. It nonetheless wants approval from shareholders of each each corporations.

Kenvue shareholders will obtain $3.50 per share in money and 0.14625 Kimberly-Clark shares for every Kenvue share held at closing. That quantities to $21.01 per share, based mostly on the closing worth of Kimberly-Clark shares on Friday.

Kimberly-Clark and Kenvue mentioned that they recognized about $1.9 billion in price financial savings which are anticipated within the first three years after the transaction’s closing.

___

AP Well being Author Tom Murphy contributed to this report.